GM informed the union of temporary layoffs starting April 14 at CAMI Assembly. Workers will return in May for limited production, and thereafter, production will cease again, with operations idling until October 2025, Unifor said.
Canada’s Competition Bureau is investigating allegations of conduct that can prevent or limit competition in the pharmacy retail market, including “patient steering” and “margin squeezing.”
Revenue rose 17% year-over-year to $17.74 billion during the quarter, surpassing a Wall Street estimate of $16.55 billion. Earnings per share stood at $2.6 versus an estimated $2.21.
JPMorgan, which holds a ‘Neutral’ rating on the stock, opined that Charles River could see disruption from customers reassessing its preclinical strategies in the near term.
Fink said in a prepared statement in the earnings report that uncertainty and anxiety about the future of markets and the economy are dominating client conversations.
Revenue rose 3% year-over-year to $20.15 billion, which failed to meet an analyst estimate of $20.76 billion, per FinChat data. Earnings per share stood at $1.39 versus a Street estimate of $1.22. Net income rose 6% to $4.89 billion.
Revenue rose 8% year-over-year to $45.31 billion, surpassing a Wall Street estimate of $44.10 billion, per FinChat data. Earnings per share came in at $5.07 versus a Street estimate of $4.65.
BNY reported a 6% year-over-year rise in first-quarter revenue to $4.79 billion, which topped a Wall Street estimate of $4.77 billion, per FinChat data. Adjusted earnings per share came in at $1.58 versus a Street expectation of $1.49.
The S&P 500's rally may be premature, warns Jeremy Siegel. Trump's tariff pause is temporary and trade tensions remain. Investors advised to be cautious.
The tariff game of U.S. President Donald Trump has resulted in a tailspin in the stock market globally. The S&P 500 Index closed below 5,000 points for the first time in almost a year and shed $5.83 trillion in market value.
U.S. District Judge Edgardo Ramos in Manhattan said the plaintiffs failed to show that Bristol Myers and Celgene Corp violated the federal Sherman antitrust law.
